Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill. …

Sep 23, 2024 · Diabetes, high blood sugar, and insulin resistance are all associated with dementia. In Alzheimer’s disease, there is evidence for insulin resistance in the brain. Thus, …

The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Epub 2019 Apr 12 PubMed. Recommends. Please login to recommend the …

May 16, 2024 · In diet-induced obesity in these mice, NT-0796 caused weight loss as potently as did the GLP1 inhibitor semaglutide, and improved markers of cardiovascular risk (Thornton et …

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9(1):157-171. PubMed. Recommends. …

Jan 8, 2025 · Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging. Ageing Res Rev. 2024 Dec;102:102582. Epub 2024 Nov 14 PubMed. Recommends. …

Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol …

Dec 1, 2023 · Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. …

Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J …

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults. BMJ Open. …